Safety overview of new disease-modifying antirheumatic drugs

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.

Original languageEnglish (US)
Pages (from-to)237-255
Number of pages19
JournalRheumatic Disease Clinics of North America
Volume30
Issue number2
DOIs
StatePublished - May 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Safety overview of new disease-modifying antirheumatic drugs'. Together they form a unique fingerprint.

  • Cite this